The full year outlook for 2015 is improved. Veloxis now expects a net loss in the range of DKK 155 - 185 million. This compares with expectations of DKK 195 - 235 million announced in connection with the annual report for 2014.
The improvement is driven by the granted Orphan Drug status which entitles Veloxis to a waiver of the FDA prescription drug user fees for Envarsus® XR, along with overall cost savings.
Cash and cash equivalents are expected to be in the range of DKK 100 – 130 million at 31 December 2015. This compares with previous expectations of DKK 55 – 95 million.
Johnny Stilou, CFO
Tel. +45 30 53 33 64
John Weinberg, EVP, CCO
Telephone: +1 732-321-3208